The FDA announced on Dec. 8, 2017, that Remel Inc voluntarily recalled its Shigella sonnei Phase 1 & 2 Agglutinating Serum because it may fail to agglutinate within the specified minimum reaction time. The agency classified the recall as Class II.
How to tell if you have it
- Brand: Remel
- Product: Remel Shigella sonnei Phase 1 & 2 Agglutinating Serum, Ref R30164201 ZH01
- Kit lot #1465529, Bottle lot #1465528; Kit lot #2118879, Bottle lot #1847290; Kit lot #2173683, Bottle lot #1847290; Kit lot #2161363, Bottle lot #1847290; Kit lot #1984639, Bottle lot #1847290; Kit lot #1738564, Bottle lot#1738565; Kit lot #1971308, Bottle lot #1738565; Kit lot #1957305, Bottle lot #1738565; Kit lot #1947930, Bottle lot #1738565; and Kit lot #1847285, Bottle lot #1738565
- Quantity: 237 units (single bottles)
- Distribution: US Nationwide
The hazard
The serum may fail to agglutinate within the specified minimum reaction time, according to the FDA.
Context
GovInfoNow's records show Remel, Inc has had 22 other recalls on record since Nov. 2, 2017. Other recent recalls of similar products include Remel GC Agar Base Recall (June 3, 2026), Remel Yeastone Broth Recall (March 24, 2026), and Remel Campy CVA Medium 100/PK recall (Feb. 5, 2026).